Literature DB >> 24981160

Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?

Yuen Ling Elaine Au1, Woon Sing Raymond Wong, Mo Yin Mok, Ho Yin Chung, Eric Chan, Chak Sing Lau.   

Abstract

Recently, the Ankylosing Spondylitis Disease Activity Score (ASDAS), a new index, has been shown to be validated and highly discriminatory in assessing ankylosing spondylitis (AS) disease activity. This study is to evaluate the performance of ASDAS in a local Chinese cohort of AS in a cross-sectional setting and to compare it with the existing instrument, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Consecutive patients with AS were recruited from a local rheumatology clinic. Data, including BASDAI, Bath Ankylosing Spondylitis Functional Index (BASFI), Visual Analogue Scale (VAS) for spinal pain, and patient and physician global assessments were gathered during clinic visit. Inflammatory markers, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and high-sensitivity (hs)-CRP were collected. ASDAS was calculated accordingly. The discriminatory capacity of BASDAI and ASDAS was compared by: (1) standardized mean difference statistics, (2) R (2) in linear regressions, and (3) area under receiver operating characteristic curve (AUC) in logistic regression models. Both ASDAS and BASDAI showed satisfactory predictive value on disease activity with reference to patient and physician global assessment. R (2) in linear regression models ranged from 0.6-0.7. Both indices also demonstrated good discriminatory capacity as evidenced by a relatively high AUC (> 0.8) under the logistic regression models using either patient or physician global assessment score ≥4 and <4 as cut off of high and low disease activity status, respectively. Although we could not demonstrate significant differences in the performance between them, subgroup analysis suggested better discriminatory ability of ASDAS in the high inflammatory marker subgroup. ASDAS and BASDAI showed similarly good performance in a cross-sectional setting in a local Chinese AS cohort. ASDAS performed better in subgroup with raised inflammatory markers.

Entities:  

Mesh:

Year:  2014        PMID: 24981160     DOI: 10.1007/s10067-014-2729-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

1.  Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.

Authors:  A Spoorenberg; D van der Heijde; E de Klerk; M Dougados; K de Vlam; H Mielants; H van der Tempel; S van der Linden
Journal:  J Rheumatol       Date:  1999-04       Impact factor: 4.666

Review 2.  Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review.

Authors:  J Ruof; G Stucki
Journal:  J Rheumatol       Date:  1999-04       Impact factor: 4.666

3.  Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis.

Authors:  M A Stone; U Payne; C Pacheco-Tena; R D Inman
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

4.  Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?

Authors:  Lihi Eder; Vinod Chandran; Hua Shen; Richard J Cook; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2010-07-13       Impact factor: 19.103

5.  Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.

Authors:  John C Davis; Désirée M F M Van der Heijde; Maxime Dougados; Jurgen Braun; John J Cush; Daniel O Clegg; Robert D Inman; Todd de Vries; Wayne H Tsuji
Journal:  J Rheumatol       Date:  2005-09       Impact factor: 4.666

6.  Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis.

Authors:  Kemal Nas; Kadir Yildirim; Remzi Cevik; Saliha Karatay; Akin Erdal; Ozlem Baysal; Zuhal Altay; Ayhan Kamanli; Yuksel Ersoy; Arzu Kaya; Bekir Durmus; Ozge Ardicoglu; Ibrahim Tekeoglu; Mahir Ugur; Aysegul Jale Sarac; Kazim Senel; Ali Gur; Salih Ozgocmen
Journal:  Int J Rheum Dis       Date:  2010-08       Impact factor: 2.454

7.  Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.

Authors:  Bente Glintborg; Mikkel Ostergaard; Niels Steen Krogh; Lene Dreyer; Hanne Lene Kristensen; Merete Lund Hetland
Journal:  Ann Rheum Dis       Date:  2010-05-28       Impact factor: 19.103

8.  Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?

Authors:  A Calin; J P Nakache; A Gueguen; H Zeidler; H Mielants; M Dougados
Journal:  Rheumatology (Oxford)       Date:  1999-09       Impact factor: 7.580

Review 9.  Patient-assessed health in ankylosing spondylitis: a structured review.

Authors:  K L Haywood; A M Garratt; P T Dawes
Journal:  Rheumatology (Oxford)       Date:  2005-02-03       Impact factor: 7.580

10.  Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

Authors:  Mirjam K de Vries; Izhar C van Eijk; Irene E van der Horst-Bruinsma; Mike J L Peters; Michael T Nurmohamed; Ben A C Dijkmans; Bouke P C Hazenberg; Gerrit J Wolbink
Journal:  Arthritis Rheum       Date:  2009-11-15
View more
  8 in total

Review 1.  Coexistence of fibromyalgia syndrome and inflammatory rheumatic diseases, and autonomic cardiovascular system involvement in fibromyalgia syndrome.

Authors:  Burhan Fatih Kocyigit; Ahmet Akyol
Journal:  Clin Rheumatol       Date:  2022-09-23       Impact factor: 3.650

2.  Evaluation of the ischemia modified albumin levels in familial Mediterranean fever patients.

Authors:  Yusuf Atabay; Zeynep Altın; Ayfer Çolak; Harun Akar
Journal:  Ir J Med Sci       Date:  2022-09-09       Impact factor: 2.089

3.  Performance characteristics of the simplified version of ankylosing spondylitis disease activity score (SASDAS).

Authors:  Dilek Solmaz; Tulay Yildirim; Okan Avci; Nazmiye Tomas; Servet Akar
Journal:  Clin Rheumatol       Date:  2015-12-16       Impact factor: 2.980

4.  Factors associated with disease-specific quality of life in Taiwanese patients with ankylosing spondylitis: a cross-sectional study.

Authors:  Ming-Chi Lu; Kuang-Yung Huang; Chien-Hsueh Tung; Bao-Bao Hsu; Cheng-Han Wu; Malcolm Koo; Ning-Sheng Lai
Journal:  BMJ Open       Date:  2019-06-09       Impact factor: 2.692

5.  Fatty corner lesions in T1-weighted magnetic resonance imaging as an alternative to sacroiliitis for diagnosis of axial spondyloarthritis.

Authors:  Ho Yin Chung; Rachel Sze Wan Yiu; Shirley Chiu Wai Chan; Kam Ho Lee; Chak Sing Lau
Journal:  BMC Rheumatol       Date:  2019-05-30

Review 6.  Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis.

Authors:  James Cheng-Chung Wei; Chin-Hsiu Liu; Jui-Cheng Tseng; Lin-Fen Hsieh; Chun-Hsiung Chen; Hsin-Hua Chen; Hung-An Chen; Ying-Chou Chen; Chung-Tei Chou; Hsien-Tzung Liao; Yi-Chun Lin; Shue-Fen Luo; Deng-Ho Yang; Kai-Jieh Yeo; Wen-Chan Tsai
Journal:  Int J Rheum Dis       Date:  2019-11-27       Impact factor: 2.454

7.  Gastrointestinal risk factors and patient-reported outcomes of ankylosing spondylitis in Korea.

Authors:  Sang-Hoon Lee; Yong-Wook Park; Jung-Yoon Choe; Kichul Shin; Seong-Ryul Kwon; Jin-Hye Cha; Young-Joo Kim; Juneyoung Lee; Tae-Hwan Kim
Journal:  Int J Rheum Dis       Date:  2019-12-29       Impact factor: 2.454

8.  The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis.

Authors:  Filiz Meryem Sertpoyraz; Ayfer Colak; Aylin Dikici; Nihan Erdinc Gunduz; Merve Zeytinli Aksit
Journal:  North Clin Istanb       Date:  2020-11-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.